
    
      IPX203 is an investigational product containing CD-LD.

      IPX203-B16-01 Study Design:

      A randomized, open-label, rater-blinded, multicenter, 2-treatment, 2-period, multiple-dose
      crossover study.

      Approximately 30 qualified IR CD-LD-experienced advanced PD subjects will be randomized.

      The study duration will be approximately 8 weeks, including the screening period.
    
  